Hologic, Inc. (HOLX) Stock Valuation — PE Analysis
Medical - Instruments & Supplies · NASDAQ
Current Price
$76.01
PE Ratio (TTM)
31.3x
Intrinsic Value
$79.1
+3.9% margin of safety
COMPETITIVE MOAT
↑Strong Brand in Women's Health
Hologic has cultivated a strong brand reputation over decades, particularly in women's health diagnostics and surgical products. This trust fosters customer loyalty and can lead to repeat business.
↑Patented Technology & IP Portfolio
The company holds numerous patents, including recent victories in breast cancer detection technology. This intellectual property creates barriers to entry for competitors and protects its market position.
↑Established Distribution & Sales Network
Hologic possesses a well-established global sales and distribution network. This infrastructure allows for efficient product delivery and customer support, creating a significant hurdle for new entrants.
INVESTMENT RISKS
↓Regulatory Scrutiny and Approval Timelines
The medical device industry is heavily regulated. Delays or rejections in regulatory approvals for new products or indications can significantly impact revenue and market access.
↓Technological Disruption and AI Integration
Rapid advancements in AI and other technologies could disrupt existing diagnostic and imaging methods. Hologic must continuously innovate to integrate new technologies and maintain its competitive edge.
↓Dependence on Key Product Lines
While diversified, Hologic's financial performance can be significantly influenced by the success and market adoption of its core product lines, such as mammography and diagnostics.
Base case
HOLX base case PE valuation
At a current price of $76.01, the base case PE valuation puts HOLX fair value near $79.1 per share. That figure assumes 7.8% yearly earnings growth, a target PE multiple of 31x, and a 10% discount rate.
Intrinsic Value
$79.1
Margin of safety
+3.9%
Expected annual return
+0.8%
Base case assumptions: 7.8% annual earnings growth, 31x target PE, 10% discount rate, 5 year projection. Data as of 2026-04-07.
This base case uses default assumptions and is not financial advice. The fair value changes significantly when the target PE or earnings growth rate changes. Open the calculator to set your own assumptions and see the full sensitivity range.
Customize the HOLX PE valuation
Adjust the target PE, earnings growth, and discount rate to see how the fair value and margin of safety for Hologic, Inc. respond.
Open PE Calculator for HOLXCompany Overview
Hologic, Inc. is a medical technology company focused on designing, producing, and marketing a diverse range of diagnostic tests, medical imaging systems, and surgical solutions. Its core mission is to enhance women's health through proactive detection and effective treatment, serving patients in the United States, across Europe, the Asia-Pacific region, and various other international markets. The company operates through four distinct business units: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Within its Diagnostics segment, Hologic provides Aptima molecular diagnostic assays for identifying infectious microorganisms, alongside Aptima viral load tests for conditions like HIV, Hepatitis C, and Hepatitis B. It also offers Aptima and Panther Fusion SARS-CoV-2 assays for detecting the virus, the ThinPrep System for cytology applications, and the Rapid Fetal Fibronectin Test to help clinicians assess the likelihood of premature birth. Furthermore, the company supplies various diagnostic tests for Group B Streptococcus. The Breast Health division delivers advanced imaging and analytical solutions, including 2D and 3D digital mammography systems with accompanying reading workstations. This segment also features minimally invasive breast biopsy guidance systems and devices, products for marking and localizing breast biopsy sites, specimen radiology tools, ultrasound solutions, connectivity options, and products supporting breast-conserving surgical procedures. For GYN Surgical needs, Hologic offers the NovaSure Endometrial Ablation System, designed to manage abnormal uterine bleeding, and the MyoSure Hysteroscopic Tissue Removal System for the excision of uterine fibroids, polyps, and other pathologies. Additionally, the Fluent Fluid Management System facilitates liquid distention during diagnostic and operative hysteroscopic interventions. The Skeletal Health segment includes the Horizon DXA, a dual-energy X-ray system, and the Fluoroscan Insight FD mini C-arm, which is utilized for minimally invasive orthopedic surgical procedures. Hologic distributes its comprehensive product portfolio through a combination of its dedicated direct sales and service teams, as well as via independent distributors and sales representatives. Established in 1985, Hologic, Inc. maintains its corporate headquarters in Marlborough, Massachusetts.
Financial Metrics — HOLX PE Stock Valuation Data
PE Ratio (TTM)
31.3x
PEG Ratio
n/m
Earnings Yield
3.19%
ROE (TTM)
11.0%
Revenue/Share (TTM)
$18.39
Debt/Equity
0.48x
Frequently Asked Questions
What is the PE ratio of HOLX?
The trailing twelve-month PE ratio of HOLX reflects how much investors pay per dollar of Hologic, Inc.'s earnings. This metric is most useful when compared to Medical - Instruments & Supplies peers and the company's own historical range.
Is HOLX overvalued based on PE ratio?
HOLX's PE of 31.3x combined with a PEG ratio of -1.33 provides a growth-adjusted perspective. HOLX has negative earnings, so its PE and PEG ratios are not meaningful here and cannot tell you whether the stock is over or undervalued. Keep in mind that PE-based valuation works best for profitable, mature companies — for high-growth or cyclical Medical - Instruments & Supplies, a DCF analysis may be more appropriate.
How do I value HOLX stock using PE ratio?
To value Hologic, Inc. using PE: (1) Compare the current PE (31.3x) against the Medical - Instruments & Supplies median to assess relative pricing, (2) check the PEG ratio (-1.33) to adjust for growth expectations, (3) review the 5-year PE range to identify where the stock sits historically, and (4) estimate fair value by multiplying a target PE by forward EPS estimates. This relative approach complements DCF's absolute valuation.
What is the PEG ratio of HOLX?
HOLX's PEG ratio is -1.33, calculated by dividing the PE ratio (31.3x) by the expected earnings growth rate. Because HOLX has negative earnings, its PEG ratio is not meaningful and should not be read as a sign of under or overvaluation. Note that PEG accuracy depends on the reliability of growth estimates.
Should I use PE ratio or DCF for HOLX stock valuation?
PE ratio gives a quick relative read — how HOLX is priced versus Medical - Instruments & Supplies peers. DCF provides an absolute value based on projected free cash flows. For the most reliable valuation, use PE as a quick comparability screen and DCF for a deeper fundamental analysis. Each method has blind spots: PE ignores capital structure and cash flow quality, while DCF is sensitive to growth and discount rate assumptions.
Learn More
- See HOLX DCF Valuation → — Intrinsic value via Discounted Cash Flow analysis
- PE Methodology — Step-by-step guide to PE ratio stock valuation
- DCF Methodology — Guide to discounted cash flow analysis
- PE Ratio — Understanding the price-to-earnings ratio
- Intrinsic Value — How to evaluate stock fair value
Related PE Valuations
All Healthcare valuationsP/E and DCF value HOLX with different methods and assumptions, so the two conclusions can differ. Compare the DCF intrinsic value.
Price as of 2026-04-07. Financial data from Financial Modeling Prep (trailing twelve months) · Valuation methodology by Charlie Wang.
This is an estimate, not investment advice.